For the 2024 consolidated annual financial statements, management anticipates a significant increase in losses in the fourth quarter due to the inclusion of Pentixapharm AG and Myelo Therapeutics GmbH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback